Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27297870 | 0.83 | KDR (0.36) | KDRSYKKCNH2ALDH1A1 | |
| SCHEMBL5465794 | 0.81 | KDR (0.35) | KDRSYKKCNH2KEAP1SMN1; SMN2 | |
| SCHEMBL5465799 | 0.74 | KEAP1 (0.32) | KEAP1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL18579046 | 0.71 | GNAO1 (0.37) | KEAP1SMN1; SMN2KDM4EALDH1A1GLA | |
| SCHEMBL18505991 | 0.71 | GNAO1 (0.37) | KEAP1SMN1; SMN2KDM4EALDH1A1GLA | |
| SCHEMBL18505992 | 0.71 | GNAO1 (0.37) | KEAP1SMN1; SMN2KDM4EALDH1A1GLA | |
| SCHEMBL5465714 | 0.71 | — | — | |
| SCHEMBL28661527 | 0.70 | CXCR4 (0.48) | KEAP1SMN1; SMN2KDM4EALDH1A1CA2 | |
| SCHEMBL28969434 | 0.70 | SLC6A2 (0.42) | KEAP1SMN1; SMN2KDM4EALDH1A1GLA | |
| SCHEMBL18497400 | 0.70 | ALDH1A1 (0.42) | KEAP1SMN1; SMN2KDM4EALDH1A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043010-A1 | Quinazoline derivatives | ASTRAZENECA UK LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043010-A1 | Quinazoline derivatives | ERBB2, ABL1, EGFR | KDR 101/4885SYK 648/4885KCNH2 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.